Nurix Therapeutics announced updated Phase 1a/1b clinical trial results for bexobrutideg (NX-5948), an oral BTK degrader, showing high response rates and good tolerability in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including those previously treated with covalent BTK inhibitors. The data, to be presented at the 68th ASH Annual Meeting, highlight durable clinical activity and support ongoing development of bexobrutideg as a potential best-in-class therapy for B-cell malignancies. Further analyses on treatment-naïve and high-risk patients will also be shared, underscoring the drug's differentiated mechanism targeting both wild-type and mutant BTK forms. This progress marks an important step toward addressing unmet needs in CLL/SLL treatment.
Nurix Therapeutics' updated clinical trial data for bexobrutideg (NX-5948) provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health-sector stocks, 94 rose and 48 fell. Notable movers include IOVA at USD 9.20 (+5.75%, typical hold time 4 days, 52% buy orders), ALMS at USD 6.20 (-5.34%, typical hold time 21 days), and OSCR at USD 36.95 (+5.00%, typical hold time 16 days, 59% buy orders).
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
